Nicole Gill, DO
Neurology · Durham, NCNPI 1548491996
Payments from drug & device makers
Across 491 payments — averaging $187.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$32K
- Amgen$23K
- Teva Pharmaceuticals USA, Inc.$20K
- Biohaven Pharmaceuticals, Inc.$8K
- Pfizer$5K
- Biohaven Pharmaceutical Holding Company Ltd.$605
- plus $2K from 24 others
What the payments were for
- Consulting fees$1,0001%
- Speaking & faculty fees$77,55084%
- Travel & lodging$2,9873%
- Food & beverage$10,27811%
- Education$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 179 | $32,337 |
| Amgen | 74 | $23,400 |
| Teva Pharmaceuticals USA, Inc. | 61 | $19,855 |
| Biohaven Pharmaceuticals, Inc. | 24 | $8,089 |
| Pfizer | 22 | $5,474 |
| Biohaven Pharmaceutical Holding Company Ltd. | 15 | $605 |
| Lundbeck LLC | 10 | $442 |
| Lilly USA, LLC | 24 | $379 |
| Upsher-smith Laboratories LLC | 16 | $261 |
| Novartis | 7 | $151 |
| Arbor Pharmaceuticals, Inc. | 7 | $112 |
| Bausch Health US, LLC | 9 | $111 |
| Assertio Therapeutics, Inc. | 7 | $103 |
| Zyla Life Sciences, Inc. | 8 | $100 |
| Avanir Pharmaceuticals, Inc. | 4 | $76 |
| Supernus Pharmaceuticals, Inc. | 2 | $75 |
| Impel Pharmaceuticals Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $33 |
| Promius Pharma LLC | 2 | $28 |
| Si-bone, Inc. | 1 | $27 |
| Scilex Pharmaceuticals Inc. | 1 | $26 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Amneal Pharmaceuticals LLC | 2 | $25 |
| Almatica Pharma LLC | 2 | $24 |
| Vertos Medical, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Tonix Medicines, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$91,922 in reported general payments places this provider in the 85th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 44 | $52,865 |
| UbrelvyUbrogepant | 33 | $36,782 |
| QuliptaAtogepant | 22 | $33,041 |
| Emgality PenGalcanezumab-Gnlm | 36 | $32,033 |
| Aimovig AutoinjectorErenumab-Aooe | 30 | $22,250 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 16 | $19,211 |
| ZavzpretZavegepant Hcl | 13 | $18,646 |
| RizatriptanRizatriptan Benzoate | 38 | $756 |
| Topiramate | 31 | $466 |
| Naratriptan Hcl | 11 | $331 |
| Ondansetron Hcl | 18 | $282 |
| Gabapentin | 13 | $186 |
| Lamotrigine | 14 | $153 |
| Amitriptyline Hcl | 15 | $123 |
| Sumatriptan Succinate | 17 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Zavzpret | $5,474 | $71,51157 claims |
| AbbVieUbrelvy, Qulipta | $32,337 | $69,82255 claims |
| Upsher-smith Laboratories LLCTopiramate | $261 | $46631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 566 neurology providers in North Carolina.
Other neurology in Durham
- Katherine PetersDurham$11M
- Vern JuelDurham$2M
- Burton ScottDurham$1.7M
- James BurkeDurham$1.5M
- Bradley RobottomDurham$1.4M
- Aatif HusainDurham$886K
- Jeffrey GuptillDurham$816K
- Kevin KahnDurham$587K
- Mark SkeenDurham$562K
- Annick DesjardinsDurham$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.